Literature DB >> 8264909

Levodopa therapeutics: new treatment strategies.

P A LeWitt1.   

Abstract

Even though levodopa can provide effective therapy for symptomatic relief of parkinsonism, many patients deteriorate over time. This change may be related to a loss of storage capability for dopamine in the brain affected by parkinsonian changes. Some of the variability in drug action is determined by its peripheral pharmacokinetics. Methods that can enhance dose-by-dose effectiveness, including controlled-release preparations and enteral infusions, have practical applications for managing "wearing-off" or peak-effect problems.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8264909

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Sustained-release of levodopa: single dose study of a new formulation.

Authors:  M Gerlach; W Kuhn; T Müller; P Klotz; H Przuntek
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Effects of dopamine uptake inhibitor MRZ-9547 in animal models of Parkinson's disease.

Authors:  Andrzej Dekundy; Flora Mela; Martine Hofmann; Wojciech Danysz
Journal:  J Neural Transm (Vienna)       Date:  2014-10-16       Impact factor: 3.575

3.  Metabolism of (-)-deprenyl and PF-(-)-deprenyl in brain after central and peripheral administration.

Authors:  A Lajtha; H Sershen; T Cooper; A Hashim; J Gaál
Journal:  Neurochem Res       Date:  1996-10       Impact factor: 3.996

Review 4.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.